|
16 Sep 2025 |
Torrent Pharma
|
Consensus Share Price Target
|
3531.60 |
3929.42 |
- |
11.26 |
buy
|
|
|
|
|
01 Aug 2024
|
Torrent Pharma
|
Geojit BNP Paribas
|
3531.60
|
3590.00
|
3205.00
(10.19%)
|
Target met |
Buy
|
|
|
|
|
24 Jul 2024
|
Torrent Pharma
|
Prabhudas Lilladhar
|
3531.60
|
3300.00
|
3145.90
(12.26%)
|
Target met |
Accumulate
|
|
|
|
|
23 Jul 2024
|
Torrent Pharma
|
Motilal Oswal
|
3531.60
|
3340.00
|
3138.70
(12.52%)
|
Target met |
Neutral
|
|
|
Torrent Pharma (TRP) delivered largely in-line 1QFY25. TRP posted robust 14.7% YoY growth in domestic formulation (DF) segment.
|
|
27 May 2024
|
Torrent Pharma
|
BP Wealth
|
3531.60
|
|
2655.25
(33.00%)
|
|
Results Update
|
|
|
|
|
27 May 2024
|
Torrent Pharma
|
ICICI Direct
|
3531.60
|
3080.00
|
2655.25
(33.00%)
|
Target met |
Buy
|
|
|
|
|
24 May 2024
|
Torrent Pharma
|
Sharekhan
|
3531.60
|
2954.00
|
2612.55
(35.18%)
|
Target met |
Buy
|
|
|
Q4FY24 results were good where sales grew by 10% y-o-y (2% below our estimates), EBITDA grew by 21% y-o-y (0.8% above our estimates) and PAT grew by 56% y-o-y (10% above our estimates).
|
|
15 Mar 2024
|
Torrent Pharma
|
BP Wealth
|
3531.60
|
3063.00
|
2594.45
(36.12%)
|
Target met |
Buy
|
|
|
|
|
05 Feb 2024
|
Torrent Pharma
|
BP Wealth
|
3531.60
|
|
2643.70
(33.59%)
|
|
Results Update
|
|
|
|
|
07 Dec 2023
|
Torrent Pharma
|
Motilal Oswal
|
3531.60
|
2160.00
|
2100.55
(68.13%)
|
Target met |
Neutral
|
|
|
|
|
02 Nov 2023
|
Torrent Pharma
|
Geojit BNP Paribas
|
3531.60
|
2189.00
|
1927.40
(83.23%)
|
Target met |
Buy
|
|
|
|
|
25 Oct 2023
|
Torrent Pharma
|
Motilal Oswal
|
3531.60
|
2050.00
|
1922.25
(83.72%)
|
Target met |
Neutral
|
|
|
|
|
24 Oct 2023
|
Torrent Pharma
|
ICICI Securities Limited
|
3531.60
|
1940.00
|
1877.30
(88.12%)
|
Target met |
Hold
|
|
|
Torrent Pharma’s (Torrent) branded generics business in India, Brazil and other countries (73% of revenue) grew 18% YoY in Q2FY24. Organic growth in India was 12% vs covered market growth of 7-8%. Spillover (~INR 250mn) from Q1FY24 and new launches aided 36% YoY growth in Brazil. Barring US (-17% QoQ to USD 30mn), all other segments posted healthy growth. Launches from Dahej (in Gujarat) and new oncology plant may lift US quarterly run-rate to USD 32-35mn ahead.
|
|
23 Oct 2023
|
Torrent Pharma
|
Sharekhan
|
3531.60
|
1972.00
|
1889.65
(86.89%)
|
Target met |
Hold
|
|
|
|
|
23 Oct 2023
|
Torrent Pharma
|
Prabhudas Lilladhar
|
3531.60
|
2250.00
|
1877.30
(88.12%)
|
Target met |
Buy
|
|
|
|
|
08 Aug 2023
|
Torrent Pharma
|
ICICI Securities Limited
|
3531.60
|
2130.00
|
2051.40
(72.16%)
|
Target met |
Hold
|
|
|
Torrent’s Q1FY24 performance was boosted by the acquisition of Curatio in India, while delay in shipments derailed growth in Brazil (sales of ~INR 250mn in Q1). Organic growth in domestic branded biz is estimated at ~8-9% led by price rise and new launches.
|
|
07 Aug 2023
|
Torrent Pharma
|
Motilal Oswal
|
3531.60
|
1960.00
|
2051.40
(72.16%)
|
Target met |
Neutral
|
|
|
|
|
05 Jun 2023
|
Torrent Pharma
|
Geojit BNP Paribas
|
3531.60
|
1933.00
|
1775.25
(98.94%)
|
Target met |
Hold
|
|
|
|
|
01 Jun 2023
|
Torrent Pharma
|
StoxBox - BP Wealth
|
3531.60
|
|
1774.80
(98.99%)
|
|
Results Update
|
|
|
Torrent Pharma reported a revenue growth of 16.9% YoY / flat QoQ to Rs. 24,910 mn and was marginally above market expectations of Rs. 24,320 mn. Domestic revenue grew 21.6% YoY, aided by strong performance of new launches in chronic therapies and integration of Curatio.
|
|
31 May 2023
|
Torrent Pharma
|
ICICI Direct
|
3531.60
|
2010.00
|
1835.80
(92.37%)
|
Target met |
Buy
|
|
|
|
|
31 May 2023
|
Torrent Pharma
|
Prabhudas Lilladhar
|
3531.60
|
1900.00
|
1835.80
(92.37%)
|
Target met |
Buy
|
|
|
|